Publication | Open Access

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

Gastrointestinal OncologyMedicineAdvanced Gastric CancerPharmacologyGastroenterologyPaclitaxel-associated Hypersensitivity ReactionsPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyThree-hour Infusion